Company Overview - Established in 2001 and listed on Shenzhen Stock Exchange in 2011, the company has total assets of CNY 8.181 billion as of Q1 2025 [1] - A key supplier in the automotive thermal management and lightweight system components sectors, focusing on high-end aluminum alloy material applications [1] Aerospace Sector - Products in the aerospace field include high-strength aluminum alloys for hydraulic, braking, sealing, heat exchange, door, and seat systems [2] - The company has received certification from major aircraft manufacturers and is actively supplying critical components, supporting domestic aerospace development [2] Future Capacity Expansion - Plans for 2024 include projects such as: - High-performance aluminum profile manufacturing for aerospace - 2 million sets of high-strength aluminum system components for new energy vehicles - 12 million lightweight aluminum parts for automotive applications - 14,000 tons of high-efficiency aluminum tubes for home air conditioning [3] Project Progress - Investment of CNY 600 million for the Northeast headquarters production base for automotive lightweight aluminum products is underway, with construction progressing as planned [4] Raw Material Price Management - The company employs a production model based on customer orders and pricing linked to aluminum ingot prices, mitigating the impact of price fluctuations [5] Profit Distribution - For the 2024 half-year profit distribution, CNY 197.5 million was allocated, with a cash dividend of CNY 1.6 per 10 shares [6][7] - For the 2024 annual profit distribution, CNY 247.2 million will be distributed at CNY 2.0 per 10 shares [7] Competitive Advantages - Major partnerships with leading companies in the automotive thermal management and lightweight systems, generating over CNY 3 billion in revenue from thermal management products, accounting for 42% of total revenue [8] - Continuous investment in technology, quality, and project planning to enhance core competitiveness [8] Future Development Strategy - The company aims to capture opportunities in high-end aluminum applications across automotive, aerospace, marine engineering, and new energy sectors, with a goal to become the largest supplier of lightweight alloy materials globally [9][10]

Group 1: Asset Acquisition and Financial Performance - The company plans to acquire 100% equity of Guangzhou Metro Engineering Consulting Company for approximately CNY 5.11 billion to enhance its engineering consulting capabilities [1] - The first quarter performance showed fluctuations due to long project cycles in rail transit design, leading to a decline compared to previous years [2] - Asset impairment provisions increased in the first quarter, influenced by macroeconomic factors and slower payment progress [2] Group 2: Profitability and Cost Management - The gross profit margin for surveying and design business improved in 2024, attributed to project completion and effective cost control measures [2] - The company aims to strengthen production operations and control costs to achieve stable performance and return value to investors [2] Group 3: Business Expansion and Innovation - The company is exploring innovative integration of rail transit and low-altitude economy, successfully obtaining feasibility studies and contracts for related projects [3][4] - An overseas division has been established to expand into markets in Vietnam, Singapore, and other regions, with recent contracts signed for projects in Serbia and Hong Kong [4] Group 4: Dividend Policy - The company plans to distribute at least 30% of its distributable profits as cash dividends annually from 2024 to 2026, considering operational conditions and future development plans [4]

Group 1: Sales and Market Performance - The sales of nicotine at the company's Jingmen facility have significantly increased compared to the same period last year, although this has not yet had a major impact on the overall business performance [1] - The sales of the antihypertensive drug, Rabeprazole enteric-coated capsules, have declined, which has significantly affected the company's performance [4] - The market competition for Sartans remains intense, with sales prices fluctuating in a low range due to various factors including supply and demand [5] Group 2: Product Development and Innovation - The company's Class 1 innovative drug, Dihydrocodeine injection, is classified as a chemical drug and is used for myocardial perfusion imaging (MPI) to diagnose and assess myocardial ischemia [2] - The core formulation product matrix covers various therapeutic areas including cardiovascular, digestive, analgesic, anti-infective, endocrine, respiratory, and anesthesia, with a focus on innovative dosage forms [3] - The company is committed to advancing green and synthetic biotechnology applications, accelerating the development and launch of generic and innovative drugs, particularly in cardiovascular and digestive systems [4] Group 3: Safety and Usage Guidelines - Dihydrocodeine injection has a good safety profile with mild adverse reactions that quickly resolve after discontinuation, making it suitable for use in myocardial perfusion imaging [2] - The specific usage of Dihydrocodeine injection should be determined by doctors based on individual patient conditions, adhering strictly to medical advice [2]

Group 1: Company Overview - Hangzhou Xingshuai Electric Co., Ltd. was listed on the Shenzhen Stock Exchange in April 2017 as a high-tech enterprise with strong innovation and R&D capabilities [2] - The company specializes in the R&D, production, and sales of various types of thermal protectors, starters, sealing terminals for refrigeration compressors, temperature controllers for small appliances, and photovoltaic components [2] Group 2: Military Business Development - The subsidiary Zhejiang Special Motor has obtained military qualifications primarily for the production of motors and integrated motor drives, aiming to open new sales channels [3] - Current orders for large UAV aviation starter integrated machines are in the orderly delivery phase, preparing for future mass production [3] Group 3: Investment and Strategic Planning - The company has acquired fund shares in Rongteng No. 2, which focuses on strategic investments in robotics, indicating a potential entry into the robotics sector [3] - The company is committed to expanding new business avenues through mergers and acquisitions, leveraging its manufacturing management experience and stable cash flow [3] Group 4: Future Growth and Profitability - The home appliance segment continues to provide stable customers and orders, with expanding application scenarios [4] - Future focus will shift towards R&D of new motor products, with increased technical and financial support for the subsidiary Zhejiang Special Motor, targeting high-efficiency permanent magnet motors and servo motors [4]

Group 1: Business Impact and Market Trends - The company's market share has been increasing post-collective procurement, but the profit margin for 2024 is still lower than before the policy implementation [1] - Since 2021, the orthopedic consumables have achieved full national procurement coverage across four major product categories: joints, spine, trauma, and sports medicine, leading to increased industry concentration [2] Group 2: Core Competitiveness - The company focuses on innovation and R&D as a core driver, increasing investment to meet clinical needs with high-quality products, which helps to enhance market share [2] - Technical services play a crucial role, with regular training for distributors to ensure high product and clinical compatibility [2] - The company leverages economies of scale to gradually reduce costs [2] Group 3: R&D Investment - R&D investment has increased due to a decline in overall revenue post-collective procurement, while maintaining previous investment levels [3] - The company invests in various orthopedic fields, including trauma, spine, joints, and sports medicine, as well as non-orthopedic areas like dental and neurosurgery [3] Group 4: Capital Expenditure Plans - The company completed its refinancing project by the end of 2024 and has no large-scale capital expenditure plans currently, having passed the peak of construction [4] Group 5: Robotics and International Market - The knee joint robot has begun clinical applications, with ongoing efforts to register other orthopedic robots [5] - The company exported products to over 60 countries, with overseas revenue of approximately 217 million yuan in 2024, accounting for 10.16% of total revenue [7] - The company is open to acquisitions to enhance its international market competitiveness [7] Group 6: Future Planning - The company aims to achieve higher market shares in trauma, spine, joints, and sports medicine, targeting top positions in each field [8] - Plans to strengthen market expansion in countries along the "Belt and Road" initiative and in Europe and the United States [8] Group 7: Infrastructure and Logistics - The company has established a logistics network across most prefecture-level cities in China, enhancing its core competitiveness [9] - Investment in logistics and digital platforms will continue, although the pace is slowing down as the construction phase concludes [9]

Group 1: Company Overview - Zhejiang Jingu Co., Ltd. is a high-tech enterprise focused on the research, production, and sales of automotive wheels, recognized as a "specialized, refined, distinctive, and innovative" enterprise in Zhejiang Province [3] - The company emphasizes technological innovation and product development, with a comprehensive research and development system [3] - The revolutionary new material, niobium micro-alloy, developed by the company, offers high strength (up to 2000 MPa), good toughness, low cost, and reduced carbon emissions, making it suitable for various applications [3] Group 2: Product Highlights - The company's Avatar low-carbon wheel is a lightweight product characterized by innovative design, high precision, strength, better balance, and durability, meeting customer demands in both passenger and commercial vehicle sectors [3] - The Avatar low-carbon wheel has gained traction in the new energy vehicle market, with multiple contracts from new energy vehicle manufacturers [3] - The company is accelerating capacity construction to meet increasing customer demand, leveraging its first-mover and scale advantages [3] Group 3: Financial Performance - For the first half of 2025, the company expects a net profit attributable to shareholders of approximately 30 million to 45 million yuan, representing a year-on-year growth of 44.06% to 116.08% [4] - The net profit after deducting non-recurring gains and losses is projected to be between 25 million and 37.5 million yuan, with a year-on-year increase of 58.09% to 137.14% [4] - The growth in performance is primarily driven by the positive performance of both traditional wheels and Avatar low-carbon wheels, with significant contributions from the latter [4] Group 4: Future Plans and Innovations - The company plans to enhance its research and development efforts in new materials and technologies, exploring applications in industries such as robotics and low-altitude aircraft [5] - There are plans for overseas expansion of the Avatar production line to better serve customers and meet growing order demands [5] - The company aims to improve its capacity layout based on market demand and existing orders, while also actively exploring overseas markets [5]

Group 1: Sales and Market Position - The company primarily sells compound fertilizers through a network of nearly 6,000 first-level distributors and over 100,000 retail outlets across rural areas in China [2] - The company has established overseas marketing networks in Southeast Asia, including Malaysia, Thailand, and Vietnam, enhancing its market presence [2] - The company aims to improve its market share by optimizing channel structures and enhancing service quality [2] Group 2: Industry Outlook - China's grain production is expected to exceed 1.4 trillion jin by 2024, supported by the national food security strategy, which will provide long-term demand for compound fertilizers [3] - The compound fertilizer industry is experiencing consolidation, with market share shifting towards leading enterprises due to increased competition and regulatory pressures on smaller firms [3] - The company is confident in the future growth of the compound fertilizer market driven by the modernization of agriculture and the rising demand for high-efficiency fertilizers [2][3] Group 3: Phosphate Utilization and Production - The company has established a complete phosphate utilization chain, producing various grades of phosphoric acid and ammonium phosphate, enhancing resource utilization [4] - The company’s phosphate rock resources total approximately 549 million tons, with planned mining capacity of 6.9 million tons per year [5] - The mining projects are progressing well, with specific timelines for production expected to be announced in future company disclosures [5] Group 4: Ammonia Project Development - The company’s ammonia project has a planned capacity of 2.7 million tons, with significant progress in construction at both the Hubei and Guangxi sites [4] - The project is expected to enhance the company's cost advantages and resource self-sufficiency, thereby strengthening its market position [4] - The Guangxi project will fill a production gap in southern China, supporting the expansion of the company's compound fertilizer market [5]

Group 1: Brain-Computer Interface (BCI) Developments - The first successful case of an interventional brain-computer interface in China was completed on June 14, helping a hemiplegic patient regain motor function [2][3] - This technology demonstrates China's independent innovation capabilities in BCI, marking a significant step in precise control, neural reconstruction, and intelligent rehabilitation [3] - Compared to invasive BCIs, interventional BCIs reduce trauma and recovery time, enhancing safety, although they capture lower intracranial EEG signals [3] Group 2: New Hospital Districts Progress - Beijing Sanbo is planning a new district with 480 beds, expected to be operational by Q1 2026, to improve service capacity [4] - The Kunming Sanbo district relocated in May 2025, upgrading facilities and introducing advanced medical equipment, enhancing diagnostic capabilities [4] - The Xi'an Sanbo district is awaiting fire safety approval to commence operations [4] - The Hunan Sanbo district is under construction, with plans for future opening [4] Group 3: Financial and Operational Insights - In Q1 2025, Beijing Sanbo's medical insurance revenue accounted for approximately 30%, with other hospitals showing higher percentages, such as Chongqing Sanbo at 66% [8] - New hospital districts are expected to increase business scale and revenue post ramp-up period, enhancing overall profit levels [5][9] Group 4: Strategic Development and Mergers - The company aims to establish over 10 group-controlled hospitals nationwide, focusing on key regions to expand its service radius and enhance industry influence [6] - Mergers will target neuro-specialty and general hospitals, particularly in the Yangtze River Delta and Pearl River Delta regions [6] Group 5: Talent Development and Training - The talent training system includes local recruitment, training in Beijing, and incentives for high-end talent to join as entrepreneurs [7] - The company provides a comprehensive platform for professional development and complex case management [7] Group 6: ESG and Community Engagement - The company engages in social responsibility by providing financial aid to impoverished patients and conducting free clinics in remote areas [13] - A new brain health community initiative was launched in May 2025, focusing on a full-service system from prevention to rehabilitation [13] Group 7: Impact of Policies and Regulations - The inclusion of certain BCI projects in the medical insurance guidelines is expected to have a long-term positive impact on revenue [14] - DRG payment systems have varying effects on different hospital types, with specialized hospitals facing less impact due to the complexity of cases [14] Group 8: Clinical Applications of BCI - Current clinical applications of BCI are in the experimental phase, focusing on neuro-regulation for conditions like Parkinson's and epilepsy [15] - Ongoing research includes potential applications for awakening patients in a vegetative state and rehabilitation for stroke victims [15]

周大生珠宝股份有限公司 投资者关系活动记录表 投资者关系活动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑现场参观 □其他(电话会议) 参与单位名称 及人员姓名 共计 3 位投资者（排名不分先后）： 高毅资产：王治璇 国泰海通：李宏科、张冰清 时 间 2025 年 7 月 8 日 地 点 总部会议室 上市公司接待人员 姓名 证券事务代表：荣欢 投资者关系活动 主要内容介绍 一、 问答环节： 投资者主要就行业情况、国家宝藏、毛利率情况、分红等问题进行 了交流，并参观了公司展厅，可参阅前次活动记录表之问答和已披露公 告。 接待过程中，公司严格按照《信息披露管理制度》等规定，保证信 息披露的真实、准确、完整、及时、公平，没有出现未公开重大信息泄 露等情况。同时，现场调研的投资者已按深交所要求签署承诺函。 附件清单（如有） 无 日期 2025 年 7 月 8 日 代码：002867 证券简称：周大生 编号：2025-030 ...

Group 1: Company Overview - The company primarily engages in the research, production, and sales of automotive motor technology and fluid technology products, aiming to become a global leader in automotive motor technology solutions [2] - The main production base is located in Ningbo, with additional production bases established in locations such as Qingyuan, Shenyang, Wuhan, the USA, and Thailand to serve distant customers [3] Group 2: Financial Performance - In 2024, the company's main business revenue reached 950.51 million CNY, with the cleaning business accounting for 46.3%, motor business for 45.6%, and other businesses for 8.1% [3] Group 3: Market and Product Insights - The traditional cleaning business has established a certain market share domestically, with growth primarily dependent on acquiring new customers [4] - The company has secured projects for active cleaning systems, with an expected production capacity of 250,000 units per year based on mass production progress [4] - Active perception cleaning systems are designed for advanced autonomous driving, requiring more complex and higher-value products compared to traditional systems [5] Group 4: Profitability and Challenges - Profit margins are subject to fluctuations due to market conditions, business structure, exchange rate changes, and raw material prices [6] - The cleaning system's profit margin is significantly influenced by market dynamics, while the motor and cleaning pump products maintain relatively stable margins even in challenging periods [6] Group 5: Research and Development - The company has developed a skilled R&D team with expertise in mechanical, electronic, control, industrial software, sensors, and intelligent manufacturing [8] - The core R&D team possesses extensive industry experience, and the company actively recruits external talent to enhance its capabilities [8]